Clinical experience with BIAsp 30: Results from the Philippine cohort of the global a1chieve study
Philippine Journal of Internal Medicine
; : 1-10, 2014.
Article
en En
| WPRIM
| ID: wpr-633430
Biblioteca responsable:
WPRO
ABSTRACT
OBJECTIVE: To evaluate the safety, effectiveness and health-related quality of life (HRQoL) parameters of A1chieve study participants in the Philippine cohort, who were treated with BIAsp 30.METHODOLOGY: A1chieve is a non-interventional, six-month, observational study of 66,726 people with type 2 diabetes mellitus (T2DM), including both insulin users and non-insulin users, started on insulin detemir, insulin aspart, or BIAsp 30 in 28 countries across four continents. The present study evaluates the safety, effectiveness and HRQoL in 1,252 subjects from the Philippine cohort of the A1chieve study who were treated with BIAsp 30.RESULTS: At baseline, the mean age, duration of diabetes and mean BMI were found to be 55.5±11.7 years, 7.2 ± 5.6 years and 25.4 ± 5.3 kg/m2, respectively. Seventy-eight percent (78%) of subjects were insulin naïve and 22% were prior insulin users. At baseline, glycemic control was poor (HbA1c = 9.9%) in the entire cohort. Overall there was a 2.7% reduction in mean HbA1c and 44.2% subjects achieved the HbA1c target of CONCLUSION: BIAsp 30 is safe and efficacious for initiating and intensifying insulin therapy for Filipino T2DM patients.
Texto completo:
1
Banco de datos:
WPRIM
Asunto principal:
Triglicéridos
/
Hemoglobina Glucada
/
Diabetes Mellitus Tipo 2
/
Insulina Aspart
/
Insulina
/
Insulina Isófana
/
LDL-Colesterol
Tipo de estudio:
Etiology_studies
/
Observational_studies
Límite:
Adult
/
Female
/
Humans
/
Male
Idioma:
En
Revista:
Philippine Journal of Internal Medicine
Año:
2014
Tipo del documento:
Article